February 22, 2024The LancetOpen Access

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial

View Full Paper

Ask AI

Bookmark

Abstract

Novel oral poliovirus vaccine type 2 (nOPV2) has been engineered to improve the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of circulating vaccine-derived polioviruses. This trial aimed to provide key safety and immunogenicity data required for nOPV2 licensure and WHO prequalification.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ochoge et al. (2024) studied this question.

synapsesocial.com/papers/68e780b7b6db6435876f35a0 https://doi.org/10.1016/s0140-6736(23)02844-1

View Full Paper

Ask AI

Bookmark

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial

Abstract

Discussion

Cite This Study

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading